Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Allied Health Professionals’ Corner
Author Reply
Book Review
Brief Communication
Case Report
Case Series
Clinical Case Report
Clinicopathological Conference
Commentary
Commentary : Patient’s Voice
Corrigendum
Editorial
Editorial – World Kidney Day 2016
Editorial Commentary
Erratum
Foreward
Guideline
Guidelines
Image in Nephrology
Images in Nephrology
In-depth Review
Letter to Editor
Letter to the Editor
Letter to the Editor – Authors’ reply
Letters to Editor
Literature Review
Nephrology in India
Notice of Retraction
Obituary
Original Article
Perspective
Research Letter
Retraction Notice
Review
Review Article
Short Review
Special Article
Special Feature
Special Feature - World Kidney Day
Systematic Review
Technical Note
Varia
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Allied Health Professionals’ Corner
Author Reply
Book Review
Brief Communication
Case Report
Case Series
Clinical Case Report
Clinicopathological Conference
Commentary
Commentary : Patient’s Voice
Corrigendum
Editorial
Editorial – World Kidney Day 2016
Editorial Commentary
Erratum
Foreward
Guideline
Guidelines
Image in Nephrology
Images in Nephrology
In-depth Review
Letter to Editor
Letter to the Editor
Letter to the Editor – Authors’ reply
Letters to Editor
Literature Review
Nephrology in India
Notice of Retraction
Obituary
Original Article
Perspective
Research Letter
Retraction Notice
Review
Review Article
Short Review
Special Article
Special Feature
Special Feature - World Kidney Day
Systematic Review
Technical Note
Varia
View/Download PDF

Translate this page into:

Commentary
27 (
4
); 245-246
doi:
10.4103/0971-4065.175977

Mucormycosis and Cytomegalovirus Co-infection in Renal Transplant Recipients

Department of Nephrology, PGIMER, Chandigarh, India

Address for correspondence: Dr. K. L. Gupta, Department of Nephrology, PGIMER, Chandigarh, India. E-mail: klgupta@hotmail.com

Read COMMENTARY-ARTICLE associated with this -

Licence

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

Disclaimer:
This article was originally published by Medknow Publications & Media Pvt Ltd and was migrated to Scientific Scholar after the change of Publisher.

Opportunistic infections have a high incidence among hematopoetic and solid organ transplant recipients with compromised cell-mediated immunity induced by immunosuppression.[1] Cytomegalovirus (CMV) infection is frequently seen in the renal transplant recipients, especially those who have received T-cell depleting antibodies.[2] CMV infection produces immuno-modulatory effects, resulting in further immunosuppression that predisposes transplant recipients to develop serious non-CMV infections, like invasive fungal infections, following transplantation.[2] Mucormycosis is a rare and life-threatening invasive fungal infection caused by fungi of the Zygomycetes class and order Mucorales.[3] Rhizopus, Mucor, and Rhizomucor are the genera most frequently identified in the posttransplant setting.[45] Based on the route of infection and symptomatology, mucormycosis may present with different clinical syndromes with the rhino-cerebral and pulmonary being more common. Gastrointestinal (GI) mucormycosis is rare, accounting for only 7%, and has a high mortality rate of 85%.[6] GI mucormycosis may occur in any part of the alimentary tract, with the stomach being most commonly involved. In a recent issue of this journal, Nandwani et al. have described an interesting case of CMV and Mucor co-infection of the GI tract within 4 weeks of an ABO-incompatible (ABOi) renal transplantation.

In an earlier issue of the journal, Nandwani et al. had described a 45-year-old man with end-stage renal disease, who underwent a live-donor ABOi renal transplant after appropriate preconditioning with immunosuppressive medications and plasmapheresis.[7] Posttransplant course was marked by presumably tacrolimus-induced biopsy-proven diffuse thrombotic microangiopathy causing delayed graft function requiring dialytic support. His condition gradually improved, but worsened again four weeks posttransplant, when he developed GI symptoms that were proven to be related to co-infection with CMV and Mucor on gastric histopathology. Unfortunately, the patient succumbed to these fatal infections.

Two interesting aspects of this case include – early occurrence of CMV and Mucor co-infection as well as its occurrence in the setting of an ABOi renal transplantation. Of note, both donor and recipient were CMV seropositive (D+/R+) before transplant. However, per the case report, it does not appear that the patient received anti-CMV prophylaxis. Given that CMV is the most common opportunistic pathogen in solid organ transplant recipients, both CMV disease, and asymptomatic viremia pose a major challenge. Attributable to its immuno-modulatory effects, it can impair graft survival by facilitating acute graft rejection and interstitial fibrosis/tubular atrophy. Guidelines recommend that patients with asymptomatic CMV viremia should receive preemptive valganciclovir therapy for significantly better graft survival.[8] However, given that the patient described in the case report by Nandwani et al. did not receive anti-CMV prophylaxis, it could possibly explain early-onset CMV infection. This is also compounded by the fact that patient received aggressive immunosuppresive therapy in the pre- and post-transplant setting of ABOi transplantation. ABOi transplant recipients are at high risk for opportunistic infections because of enhanced immunosuppression.[910]

Mucormycosis and CMV infection can occur individually; a concomitant infection of the two as reported by Nandwani et al. is rare and was first reported by Ju et al. in 2001.[11] Independent risk factors for mucormycosis present in this patient include aggressive immunosuppression particularly with T-cell depleting agents, prolonged Intensive Care Unit stay, and renal dysfunction.[12] Initial graft dysfunction requiring augmented immunosuppression, as seen in this patient, has also been shown to be an independent predictor of mucormycosis.[12] Besides, further immunosuppressive effects of CMV infection could also have contributed to the development of this fatal invasive infection.

This case thus highlights the morbidity and mortality of mucormycosis and CMV co-infection in ABOi renal transplant recipients receiving aggressive immunosuppression. It also exemplifies the role of anti-CMV prophylaxis in patients, given the devastating effects of CMV infection on posttransplant outcomes. Improvement in patient outcomes entails preventive strategies with a high index of suspicion and early management of infection.

References

  1. , . Infection in solid-organ transplant recipients. N Engl J Med. 2007;357:2601-14.
    [Google Scholar]
  2. , , , , . Cytomegalovirus disease in kidney transplant recipients: Incidence, clinical profile, and risk factors. Transplant Proc. 2012;44:694-700.
    [Google Scholar]
  3. , , , , , . Mucormycosis (zygomycosis) of renal allograft. Clin Kidney J. 2012;5:502-7.
    [Google Scholar]
  4. , , , , , , . Epidemiology and outcome of zygomycosis: A review of 929 reported cases. Clin Infect Dis. 2005;41:634-53.
    [Google Scholar]
  5. , , , , , , . Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis. 2012;54(Suppl 1):S23-34.
    [Google Scholar]
  6. , , , , , , . Gastrointestinal zygomycosis: A report of three cases. Mycopathologia. 2007;164:35-8.
    [Google Scholar]
  7. , , , , . Invasive gastric mucormycosis and cytomegalovirus infection in an ABO incompatible renal transplant recipient. Indian J Nephrol. 2015;25:373-6.
    [Google Scholar]
  8. , , , , , , . International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation. 2010;89:779-95.
    [Google Scholar]
  9. , , , , , , . Increase of infectious complications in ABO-incompatible kidney transplant recipients – A single centre experience. Nephrol Dial Transplant. 2011;26:4124-31.
    [Google Scholar]
  10. , , , , , , . Early clinical complications after ABO-incompatible live-donor kidney transplantation: A national study of medicare-insured recipients. Transplantation. 2014;98:54-65.
    [Google Scholar]
  11. , , , , , , . Successful treatment of massive lower gastrointestinal bleeding caused by mixed infection of cytomegalovirus and mucormycosis in a renal transplant recipient. Am J Nephrol. 2001;21:232-6.
    [Google Scholar]
  12. , , , , , , . Zygomycosis in solid organ transplant recipients: A prospective, matched case-control study to assess risks for disease and outcome. J Infect Dis. 2009;200:1002-11.
    [Google Scholar]

    Fulltext Views
    281

    PDF downloads
    480
    View/Download PDF
    Download Citations
    BibTeX
    RIS
    Show Sections